View in EDS HTML Full Text PDF Full Text

Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies.

Saved in:
Bibliographic Details
Title: Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies.
Authors: Hu, Xingsheng1 (AUTHOR), Zhang, Shucai2 (AUTHOR), Ma, Zhiyong3 (AUTHOR), Feng, Jifeng4 (AUTHOR), Wu, Lin5 (AUTHOR), Lv, Dongqing6 (AUTHOR), Zhou, Jianying7 (AUTHOR), Zhang, Xiaodong8 (AUTHOR), Liu, Li9 (AUTHOR), Yu, Qitao10 (AUTHOR), Liao, Wangjun11 (AUTHOR), Zhang, Yiping12 (AUTHOR), Wang, Xiang13 (AUTHOR), Cheng, Ying14 (AUTHOR), Niu, Hongrui15 (AUTHOR), Wang, Ziping16 (AUTHOR), Wang, Dong17 (AUTHOR), Huang, Cheng18 (AUTHOR), Liu, Chunling19 (AUTHOR), Zhao, Hui20 (AUTHOR)
Source: BMC Medicine. 4/28/2023, Vol. 21 Issue 1, p1-11. 11p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:17417015
DOI:10.1186/s12916-023-02865-z